ACADIA PHARMACEUTICALS INC — Director's Dealing 2016

Dec 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2016-12-27

Reporting Person: Baity Glenn (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-27	Common Stock	M	9800	$1.55	Acquired	81363	Direct
2016-12-27	Common Stock	S	9800	$30.4565	Disposed	71563	Direct
2016-12-28	Common Stock	M	5500	$1.62	Acquired	77063	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-27	Stock Option (right to buy)	$1.55	M	9800	Disposed	2020-03-11	Common Stock (9800)	Direct
2016-12-28	Stock Option (right to buy)	$1.62	M	5500	Disposed	2021-03-24	Common Stock (5500)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $30.60 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F3: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.